Omeros Corporation (OMER)
Chart Events
Performance Outlook
| Previous Close | 14.24 |
| Open | 14.36 |
| Bid | 13.85 x 1400 |
| Ask | 14.79 x 1100 |
| Day's Range | 13.95 - 14.38 |
| 52 Week Range | 9.25 - 25.46 |
| Volume | 210,159 |
| Avg. Volume | 548,658 |
| Market Cap | 884.44M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.44 |
| Earnings Date | Aug 09, 2021 - Aug 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.43 |
Fair Value
Related Research
- Benzinga
Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients
Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Data were shared at the European Hematology Association (EHA). 61% of the intent-to-treat (ITT) population (any patient receiving at least one dose of narsoplimab) and 74% of the per-protocol (PP) population (those patients receiving over four weeks of
- Business Wire
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
SEATTLE, Jun 14, 2021--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 26th Congress of the European Hematology Association (EHA). The presentation, entitled Narsoplimab (OMS721) Treatment Contributes to Improvements in Organ Function in Adult P
- Zacks
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
Omeros (OMER) announces initial results from a phase I study of OMS906.
